Home › Funds › ORBIMED ADVISORS LLC › CRNX
ORBIMED ADVISORS LLC position in CRNX
CRINETICS PHARMACEUTICALS IN
ORBIMED ADVISORS LLC reported holding 999,000 shares of CRNX (CRINETICS PHARMACEUTICALS IN) in its Q2 2026 13F filing — a position valued at US$37.4M, representing 0.75% of its reported portfolio and ranking #37 among its reported holdings. ORBIMED ADVISORS LLC has disclosed CRNX holdings in 12 of the last 12 reported quarters, going back to Q3 2023.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How ORBIMED ADVISORS LLC's CRNX position evolved
ORBIMED ADVISORS LLC first disclosed a stake in CRNX in Q3 2023 at 2,896,074 shares (US$86.1M). Across 12 filings, ORBIMED ADVISORS LLC increased the stake 2 time(s), trimmed it 6 time(s) and left it unchanged 3 time(s). The most recent filing (Q2 2026) shows 999,000 shares valued at US$37.4M. Notable position changes include a 42% trim in Q4 2023, a 91% trim in Q3 2025, a 899% increase in Q4 2025.
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2023 | 2.90M | $86.13M | New |
| Q4 2023 | 1.67M | $59.32M | Reduce |
| Q1 2024 | 1.39M | $64.83M | Reduce |
| Q2 2024 | 1.28M | $57.37M | Reduce |
| Q3 2024 | 1.05M | $53.66M | Reduce |
| Q4 2024 | 999.00K | $51.08M | Reduce |
| Q1 2025 | 999.00K | $33.51M | Hold |
| Q2 2025 | 1.15M | $33.05M | Add |
| Q3 2025 | 100.00K | $4.17M | Reduce |
| Q4 2025 | 999.00K | $46.50M | Add |
| Q1 2026 | 999.00K | $36.28M | Hold |
| Q2 2026 | 999.00K | $37.38M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About CRNX and 13F data
CRNX (CRINETICS PHARMACEUTICALS IN) is a company whose sector is not yet classified in our data. 37 other funds we track also report a position in CRNX — the largest reported positions include Farallon Capital Management (US$336.4M), FARALLON CAPITAL MANAGEMENT, L.L.C. (US$336.4M), DRIEHAUS CAPITAL MANAGEMENT LLC (US$241.9M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding CRNX
- Farallon Capital Management 8.99M sh · $336.37M · Q2 2026
- FARALLON CAPITAL MANAGEMENT, L.L.C. 8.99M sh · $336.37M · Q2 2026
- DRIEHAUS CAPITAL MANAGEMENT LLC 6.46M sh · $241.87M · Q2 2026
- Bellevue Group AG 2.62M sh · $98.04M · Q2 2026
- BAKER BROS. ADVISORS LP 2.35M sh · $87.99M · Q2 2026
- Siren, L.L.C. 1.42M sh · $53.17M · Q2 2026
- First Light Asset Management, LLC 1.36M sh · $50.92M · Q2 2026
- Novo Holdings A/S 1.32M sh · $49.39M · Q2 2026
- ADAR1 Capital Management, LLC 1.22M sh · $45.73M · Q2 2026
- MONTANOVA CAPITAL, LLC 1.19M sh · $44.39M · Q2 2026
More on ORBIMED ADVISORS LLC
FAQ
How long has ORBIMED ADVISORS LLC held CRNX?
ORBIMED ADVISORS LLC has disclosed CRNX holdings in 12 of the last 12 reported quarters, going back to Q3 2023.
What is ORBIMED ADVISORS LLC's current position in CRNX?
As of Q2 2026, ORBIMED ADVISORS LLC holds 999.00K shares of CRNX (CRINETICS PHARMACEUTICALS IN), valued at $37.38M, representing 0.75% of its reported portfolio and ranking #37.
Has ORBIMED ADVISORS LLC been buying or selling CRNX?
In the latest 13F filing (Q2 2026), ORBIMED ADVISORS LLC held unchanged its position in CRNX.
Which other funds hold CRNX?
Other major institutional holders of CRNX include Farallon Capital Management, FARALLON CAPITAL MANAGEMENT, L.L.C., DRIEHAUS CAPITAL MANAGEMENT LLC, among 37 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.